Terrance Mcguire Sells 86,545 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $0.48, for a total value of $41,541.60. Following the sale, the director now owns 3,170,231 shares in the company, valued at approximately $1,521,710.88. This trade represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Down 4.0 %

NASDAQ:IVVD opened at $0.44 on Thursday. Invivyd, Inc. has a twelve month low of $0.40 and a twelve month high of $5.20. The company has a fifty day moving average of $0.70 and a 200-day moving average of $0.95. The firm has a market capitalization of $53.00 million, a P/E ratio of -0.23 and a beta of 0.53.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC boosted its position in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after purchasing an additional 75,780 shares in the last quarter. State Street Corp boosted its holdings in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in Invivyd in the third quarter valued at approximately $27,000. Cubist Systematic Strategies LLC grew its stake in Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Invivyd during the second quarter valued at approximately $115,000. 70.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IVVD. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. HC Wainwright lowered their target price on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley decreased their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Invivyd has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.